



NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Emerald Announces Closing of \$13.8 Million Bought Deal

VICTORIA, BC, February 10, 2017 – Emerald Health Therapeutics Inc. (TSXV: EMH) ("Emerald" or the "Company") is pleased to announce the closing today of its public offering (the "Offering") announced on February 1 and 2, 2017. Pursuant to the Offering, the Company has issued 10,235,000 units (the "Units") at a price per Unit of \$1.35 (the "Offering Price"), for gross proceeds of \$13,817,250. Dundee Capital Partners (the "Underwriter") acted as underwriter for the Offering. The 10,235,000 Units issued include 1,335,000 Units issued and sold pursuant to the over-allotment option granted by the Company to the Underwriter, which was exercised in full.

Each Unit consists of one common share of the Company (a "Share") and one-half of one common share purchase warrant (each full warrant, a "Warrant"). Each Warrant entitles the holder thereof to acquire one Share at a price of \$2.00 per Share for a period of 24 months following the closing of the Offering. In the event that the closing price of the Company's Shares on the TSX Venture Exchange is greater than \$2.50 per Share for a period of 20 consecutive trading days, the Company may accelerate the expiry date of the Warrants by giving notice to the holders thereof and in such case the Warrants will expire on the 30th day after such notice is given.

Emerald issued to the Underwriter a total of 307,050 compensation options in connection with the Offering. Each such compensation option entitles the holder to acquire a Unit at a price of \$1.35 per Unit for a period of 24 months following the closing of the Offering.

The Company intends to use the net proceeds of the Offering to accelerate facility expansion and for working capital and general corporate purposes.

The Units were offered by way of a base shelf prospectus and a shelf prospectus supplement (together, the "Prospectus") filed in all of the provinces of Canada, except Quebec.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States *Securities Act of 1933*, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the United States *Securities Act of 1933*, as amended, and applicable state securities laws.

Emerald Health Therapeutics Inc.

Emerald Health Therapeutics, Inc. operates primarily through Emerald Health Botanicals Inc. ("Botanicals"), a wholly owned subsidiary of the Company and a Licensed Producer under the Access to Cannabis for Medical Purposes Regulations (the "ACMPR"). Botanicals is authorized to cultivate and sell



both dried medical cannabis flowers and medical cannabis oils in Canada. Botanicals currently operates an indoor cultivation facility in Victoria, British Columbia, and plans to construct a much larger purpose built hybrid greenhouse facility on 32 acres in metro Vancouver. Botanicals prides itself on being one of Canada's most medically focused licensed producers and on having one of the industry's most qualified management teams with respect to pharmaceutical drug discovery, development and distribution. Botanicals intends to capture unique niches in both the medical and future adult use cannabis markets through its proprietary strains, defensible intellectual property, and superb client experience.

Please visit <https://www.emeraldhealth.ca/> for more information.

Cautionary Statements Regarding Forward Looking Information

Certain statements in this press release constitute forward-looking statements, within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are "forward-looking statements".

We caution you that such "forward-looking statements" involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements. Forward-looking statements include, but are not limited to, the use of proceeds from the Offering.

Emerald Health Therapeutics Inc. does not intend, and does not assume any obligation, to update these forward-looking statements except as required by law. These forward-looking statements involve risks and uncertainties relating to, among other things, the ability of the Company to negotiate and complete future funding transactions; variations in market conditions; and other risk factors described in the Prospectus and the Company's other filings with the applicable Canadian securities regulators, which may be viewed at www.sedar.com. Actual results may differ materially from those expressed or implied by such forward-looking statements.

Sandy Pratt, CFO
250-818-9838
invest@emerald.care

"Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release."